Lacosamide Amarox

Lacosamide, the active ingredient in Lacosamide Amarox, is a anti‑epileptic presented as an oral tablet for oral use. It treats partial‑onset seizures in adult patients who require adjunctive therapy.\n\nGNH India supplies Lacosamide Amarox as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lacosamide is an anti‑epileptic drug indicated for the management of focal seizure disorders.\n\nPartial‑onset seizures: reduces seizure frequency when used as add‑on therapy.\nAdjunctive therapy in epilepsy: improves overall seizure control in patients with refractory focal epilepsy.\nFocal seizures: stabilises neuronal excitability to prevent seizure propagation.

Lacosamide may cause a range of adverse reactions, some of which are more frequent than others.\n\nCommon Side Effects:\n- Dizziness\n- Nausea\n- Headache\n- Fatigue\n- Diplopia (double vision)\n- Somnolence\n\nSerious or Rare Side Effects:\n- Cardiac arrhythmia or atrioventricular block\n- Severe skin reactions such as Stevens‑Johnson syndrome\n- Suicidal thoughts or behavior\n- Significant liver enzyme elevation\n- Blood dyscrasias (e.g., agranulocytosis)\n- Severe hypersensitivity reactions

Before initiating therapy, several safety considerations should be reviewed.\n\nRenal impairment: adjust monitoring and consider dose modification.\nHepatic impairment: use with caution and monitor liver function.\nConcomitant antiepileptic drugs: monitor for reduced efficacy or increased toxicity.\nPregnancy: risk category unknown; discuss potential benefits and risks with a healthcare professional.\nDriving and operating machinery: may cause dizziness; avoid until individual response is known.\nStore at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Lacosamide can interact with other medicines, requiring attention to avoid reduced effectiveness or increased toxicity.\n\nMajor Interactions (Avoid):\n- Carbamazepine: may lower lacosamide plasma levels.\n- Phenytoin: may reduce lacosamide efficacy.\n- Phenobarbital: may decrease lacosamide concentration.\n- Rifampin: may increase lacosamide clearance.\n- Hormonal contraceptives: may reduce contraceptive effectiveness.\n\nModerate Interactions (Monitor Closely):\n- CNS depressants (e.g., benzodiazepines): additive sedation.\n- Alcohol: may enhance dizziness and drowsiness.\n- Other sodium‑channel blockers: potential additive cardiac effects.\n- QT‑prolonging agents: monitor ECG for arrhythmia risk.